Two Sigma Securities’s Editas Medicine EDIT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-13,100
Closed -$918K 1085
2020
Q4
$918K Buy
+13,100
New +$538K 0.02% 431
2020
Q1
Sell
-16,200
Closed -$480K 1592
2019
Q4
$480K Buy
16,200
+5,800
+56% +$145K ﹤0.01% 1468
2019
Q3
$236K Sell
10,400
-19,700
-65% -$488K ﹤0.01% 1738
2019
Q2
$745K Buy
30,100
+17,100
+132% +$408K 0.01% 880
2019
Q1
$318K Buy
+13,000
New +$294K ﹤0.01% 1149

Other funds holding EDIT

Two Sigma Securities's EDIT Position: Q1 2026 in Review

Two Sigma Securities reduced its Editas Medicine (EDIT) stake by 76% in Q1 2026, selling an estimated $70.7K and leaving 10,459 shares worth $25.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1338.

Two Sigma Securities first reported a position in EDIT in Q4 2019 and has held it in 5 quarters since. The position peaked at $952K in Q4 2019. 208 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

  • Two Sigma Securities held 10,459 shares of Editas Medicine worth $25.8K as of Q1 2026.
  • Two Sigma Securities sold 33,411 Editas Medicine shares in Q1 2026, an estimated $70.7K.
  • Editas Medicine made up ﹤0.01% of Two Sigma Securities's portfolio in Q1 2026, its #1338 holding.
  • Two Sigma Securities first reported a position in Editas Medicine in Q4 2019 and has held it in 5 quarters since.
  • Two Sigma Securities's Editas Medicine position peaked at $952K in Q4 2019.
  • 208 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.